ABB
5.6.2019 09:02:09 CEST | Business Wire | Press release
An independent study by marine consultancy Deltamarin revealed that the ABB Azipod® electric propulsion system for ferries could save up to $1.7 million in annual fuel costs per vessel, strengthening Azipod® propulsion’s market-leading position in sustainable marine technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005120/en/
By simulating a transit on seven existing ferry routes, researchers found that a ferry equipped with twin 10 MW mid-power range Azipod® units consumed less fuel compared to a similar vessel powered by a traditional shaftline propulsion system. Lower fuel consumption also means that the Azipod®-powered ferry would reduce CO2 emissions – by approximately 10,000 tons per year. This is equivalent to the amount of carbon dioxide emitted by about 2,200 passenger cars annually.
The global ferry industry, which transports 2.1 billion passengers every year, according to trade association Interferry, is facing increased pressure to meet the International Maritime Organization’s target of reducing annual emissions by 30 percent by 2025.
To help ferries improve energy efficiency and lower emissions, ABB is launching a new series of mid-power range Azipod® propulsion systems in June 2019. The latest Azipod® series will be available in the 7.5 to 14.5 MW power range and will fill the gap between the low and high-power range of Azipod® propulsors already in the market.
“We are continuously strengthening our portfolio of electric, digital and connected solutions that maximize the potential of ships and ultimately enable more sustainable operations,” said Peter Terwiesch, President of the Industrial Automation business at ABB, which offers solutions for a wide range of industries, including marine. “With the launch of the mid-power range Azipod® propulsion, we will be able to empower more shipowners to improve the performance of their vessels while lowering environmental impact.”
The Azipod® propulsion system, where the electric drive motor is in a submerged pod outside the ship hull, can rotate 360 degrees to increase maneuverability and operating efficiency, and has a proven ability to cut fuel consumption by up to 20 percent compared to traditional shaftline propulsion systems. Due to minimal noise and vibration, Azipod® propulsion also improves passenger and crew comfort. Azipod® propulsion systems have accumulated more than 15 million running hours, saving over 700,000 tons of fuel in the passenger cruise segment alone.
The latest Azipod® ‘M’ series is equipped with ABB’s fourth generation permanent magnet motors that draw on proven Azipod® propulsion technologies and have been refined to further increase power and maximize efficiency. The design simplicity of the system provides increased robustness and reliability, at the same time allowing for ease of maintenance.
With this expansion, the Azipod® propulsion family now covers the power range of 1-22 MW and is available for vessels from smaller crafts to icebreakers capable of independently operating in the harshest conditions. In addition to ferries and RoPax vessels that carry both vehicles and passengers, the mid-power range will also be applicable for larger offshore construction vessels, midsize cruise ships and shuttle tankers.
ABB – one of the world’s leading enablers of sustainable transportation – has already received several breakthrough orders in the ferry segment, including an Azipod® propulsion system for an LNG-powered Viking Line vessel due for delivery next year. Azipod® propulsion was also preferred by Finnish shipping company Wasaline for a recently ordered dual-fuel and battery power ferry, which will operate between Sweden and Finland.
“Building a future-proof, robust RoPax ferry requires proven technology that enables energy efficiency, saves valuable onboard space and provides increased passenger comfort. These features, coupled with superior maneuverability that would allow the ferry to operate a precise schedule crucial for a busy route, have made ABB’s Azipod® propulsion a natural choice for our newbuild project,” – said Peter Ståhlberg, CEO of Wasaline.
With over half of its global revenue generated from solutions that directly address the causes of climate change, ABB is at the forefront of sustainable development.
To watch the video, click here .
A summary of the Deltamarin study can be found here .
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005120/en/
Contact:
ABB Ltd Affolternstrasse 44 8050 Zurich Switzerland
Media Relations Phone: +41 43 317 71 11 Email: media.relations@ch.abb.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
